___

• Winum J Y, Scozzafava A, Montero J L,Supuran C T. Therapeutic potential of sulfamides as enzyme inhibitors. Journa., 2006. 26(6): p. 767-92.
• Bendjeddou A, Djeribi R, Regainia Z,Aouf N. N, N’-substituted 1, 2, 5 thiadiazolidine 1, 1-dioxides: synthesis, selected chemical and spectral proprieties and antimicrobial evaluation. Journa., 2005. 10(11): p. 1387-1398.
• Villalba M L, Palestro P, Ceruso M, Gonzalez Funes J L, Talevi A, Bruno Blanch L, Supuran C T,Gavernet L. Sulfamide derivatives with selective carbonic anhydrase VII inhibitory action. Journa., 2016. 24(4): p. 894-901.
• Abbaz T, Bendjeddou A, Gouasmia A, Bouchouk D, Boualleg C, Kaouachi N, Inguimbert N,Villemin D. Synthesis, Characterization and Antibacterial Activity of Cyclic Sulfamide Linked to Tetrathiafulvalene (TTF). Journa., 2014. 11(1): p. 59-63.
• Spaltenstein A, Almond M R, Bock W J, Cleary D G, Furfine E S, Hazen R J, Kazmierski W M, Salituro F G, Tung R D,Wright L L. Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds. Journa., 2000. 10(11): p. 1159-62.
• Zhong J, Gan X, Alliston K R,Groutas W C. Design, synthesis, and in vitro evaluation of inhibitors of human leukocyte elastase based on a functionalized cyclic sulfamide scaffold. Journa., 2004. 12(3): p. 589-93.
• Kim S J, Park H B, Lee J S, Jo N H, Yoo K H, Baek D, Kang B-w, Cho J-H,Oh C-H. Novel lβ-methylcarbapenems having cyclic sulfonamide moieties: Synthesis and evaluation of in vitro antibacterial activity. Journa., 2007. 42(9): p. 1176-1183.
• Supuran C T, Scozzafava A,Agents M. Carbonic anhydrase inhibitors. Journa., 2001. 1(1): p. 61-97.
• Gediz Erturk A,Bekdemir Y. Microwave-Assisted Synthesis of Some Substituted Sulfamides. Journa., 2014. 189(2): p. 285-292.
• Castro J L, Baker R, Guiblin A R, Hobbs S C, Jenkins M R, Russell M G N, Beer M S, Stanton J A, Scholey K, Hargreaves R J, Graham M I,Matassa V G. Synthesis and Biological-Activity of 3-[2-(Dimethylamino)Ethyl]-5-[(1,1-Dioxo-5-Methyl-1,2,5-Thiadiazolidin-2-Yl)-Methyl]-1h-Indole and Analogs - Agonists for the 5-Ht1d Receptor. Journa., 1994. 37(19): p. 3023-3032.
• Turnidge J,Paterson D L. Setting and revising antibacterial susceptibility breakpoints. Journa., 2007. 20(3): p. 391-408, table of contents.
• Bell S, Gatus B, Pham J,Rafferty D. Antibiotic susceptibility testing by the CDS method. Journa., 1999.
• Arslan N B, Erturk A G, Kazak C,Bekdemir Y. 3-Amino-4-[4-(dimethyl-amino)-phen-yl]-4,5-dihydro-1,2,5-thia-diazole 1,1-dioxide. Journa., 2011. 67(Pt 7): p. o1736.
• Lee C H, Korp J D,Kohn H. 3-Oxo-and 3-imino-4-substituted-1, 2, 5-thiadiazolidine 1, 1-dioxides: synthesis, spectral properties, and selected chemistry. Journa., 1989. 54(13): p. 3077-3083.
• CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, Ninth Edition (M07-A9). 2012, CLSI Wayne, PA, USA.
• CLSI. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes—Second Edition: Approved Standard M24-A2. 2011, CLSI Wayne, PA, USA.
• CLSI. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline, Fourth Edition (M23) 2016, CLSI Wayne, PA, USA.
• CLSI. Performance standards for antimicrobial susceptibility testing; twenty-six informational supplement (M100S). 2016, CLSI Wayne, PA, USA.
• Wiegand I, Hilpert K,Hancock R E. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Journa., 2008. 3(2): p. 163-75.
• Brown-Elliott B A, Biehle J, Conville P S, Cohen S, Saubolle M, Sussland D, Wengenack N, Kriel K, Bridge L, McNulty S, Vasireddy R,Wallace R J, Jr. Sulfonamide resistance in isolates of Nocardia spp. from a US multicenter survey. Journa., 2012. 50(3): p. 670-2.
• Clark N M, Reid G E,Practice A S T I D C o. Nocardia infections in solid organ transplantation. Journa., 2013. 13 Suppl 4(s4): p. 83-92.
• Schlaberg R, Fisher M A,Hanson K E. Susceptibility profiles of Nocardia isolates based on current taxonomy. Journa., 2014. 58(2): p. 795-800.
• Welsh O, Vera-Cabrera L,Salinas-Carmona M C. Current treatment for nocardia infections. Journa., 2013. 14(17): p. 2387-98.
• Southwick F S. Infectious Diseases: Nocardia Species. Overview: What Every Clinician Needs To Know. [Access date: 19.02.2019]; Available from: https://www.clinicalpainadvisor.com/infectious-diseases/nocardia-species/article/610646/?utm_source=TrendMD&DCMP=OTC-CPA_trendmd&dl=0.
• Argyropoulou I, Geronikaki A, Vicini P,Zani F. Synthesis and biological evaluation of sulfonamide thiazole and benzothiazole derivatives as antimicrobial agents. Journa., 2009. 6: p. 89-102.
• Bendjeddou A, Abbaz T, Ayari A, Benahmed M, Gouasmia A,Villemin D. Antibacterial Activity and Global Reactivity Descriptors of some Newly Synthesized Unsymmetrical Sulfamides. Journa., 2016. 32(2): p. 799-806.
• Berredjem M, Bouchareb F, Kaki S A, Dekhil M,Aouf N E. Synthesis and antibacterial activity of novel N-acylsulfonamides. Journa., 2017. 10: p. S1095-S1099.
• Gediz Ertürk A., Atli Şekeroğlu Z., Kontaş Yedier S.,V. Ş. 3-Amino-4-[4-(Dimetilamino)Fenil]-4,5-Dihidro-1,2,5-Tiyadiazol 1,1-Dioksit Bileşiğinin Kromozom Hasarı Üzerindeki Etkisi. in Uluslararası Katılımlı “5. İlaç Kimyası: İlaç Etkin Maddesi Tasarımı, Sentezi, Üretimi Ve Standardizasyonu Kongresi 30.03.2017 - 02.04.2017 of Conference. Turkey, Antalya.